Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort.
dementias
neuroimaging
plasma biomarkers
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
revised:
18
03
2024
received:
08
11
2023
accepted:
19
03
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
15
5
2024
Statut:
aheadofprint
Résumé
We evaluated associations between plasma and neuroimaging-derived biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities. We examined plasma biomarkers (neurofilament light chain, glial fibrillary acidic protein, amyloid beta [Aβ] 42/40, phosphorylated tau 181) and neuroimaging measures of amyloid deposition (Aβ-positron emission tomography [PET]), total brain volume, white matter hyperintensity volume, diffusion-weighted fractional anisotropy, and neurite orientation dispersion and density imaging free water. Participants were adjudicated as cognitively unimpaired (CU; N = 299), mild cognitive impairment (MCI; N = 192), or dementia (DEM; N = 65). Biomarkers were compared across groups stratified by diagnosis, sex, race, and APOE ε4 carrier status. General linear models examined plasma-imaging associations before and after adjusting for demographics (age, sex, race, education), APOE ε4 status, medications, diagnosis, and other factors (estimated glomerular filtration rate [eGFR], body mass index [BMI]). Plasma biomarkers differed across diagnostic groups (DEM > MCI > CU), were altered in Aβ-PET-positive individuals, and were associated with poorer brain health and kidney function. eGFR and BMI did not substantially impact associations between plasma and neuroimaging biomarkers. Plasma biomarkers differ across diagnostic groups (DEM > MCI > CU) and are altered in Aβ-PET-positive individuals. Altered plasma biomarker levels are associated with poorer brain health and kidney function. Plasma and neuroimaging biomarker associations are largely independent of comorbidities.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : P30AG072947
Pays : United States
Organisme : NIH HHS
ID : T32AG033534
Pays : United States
Organisme : NIH HHS
ID : P30AG049638
Pays : United States
Organisme : NIH HHS
ID : U24AG021886
Pays : United States
Organisme : NIH HHS
ID : U01AG057195
Pays : United States
Organisme : NIH HHS
ID : P30AG072976
Pays : United States
Organisme : NIH HHS
ID : RD005665
Pays : United States
Organisme : NIH HHS
ID : RD006263
Pays : United States
Organisme : NIH HHS
ID : U54AG054345
Pays : United States
Organisme : NIH HHS
ID : U19AG074879
Pays : United States
Organisme : NIH HHS
ID : R01AG072474
Pays : United States
Organisme : NIH HHS
ID : U54AG065181
Pays : United States
Organisme : NIH HHS
ID : R01AG068193
Pays : United States
Organisme : NIH HHS
ID : U24AG082930
Pays : United States
Organisme : NIH HHS
ID : R01AG077202
Pays : United States
Organisme : NIH HHS
ID : U01AG082350
Pays : United States
Organisme : Michael J Fox Foundation
ID : MJFF-023365
Informations de copyright
© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Alcolea D, Delaby C, Muñoz L, et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J Neurol Neurosurg Psychiatry. 2021;92(11):1206‐1214. doi:10.1136/jnnp‐2021‐326603
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131‐144. doi:10.1038/nrneurol.2010.4
Smirnov DS, Ashton NJ, Blennow K, et al. Plasma biomarkers for Alzheimer's disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022;143(4):487‐503. doi:10.1007/s00401‐022‐02408‐5
Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood‐based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66‐77. doi:10.1016/S1474‐4422(21)00361‐6
Pichet Binette A, Janelidze S, Cullen N, et al. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403‐1414. doi:10.1002/alz.12787. Published online 2022.
Syrjanen JA, Campbell MR, Algeciras‐Schimnich A, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128‐1140. doi:10.1002/alz.12466
Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28(7):1398‐1405. doi:10.1038/s41591‐022‐01822‐2
O'Bryant SE, Xiao G, Edwards M, et al. Biomarkers of Alzheimer's disease among Mexican Americans. J Alzheimers Dis. 2013;34(4):841. doi:10.3233/JAD‐122074
Coffin C, Suerken CK, Bateman JR, et al. Vascular and microstructural markers of cognitive pathology. Alzheimers Dement. 2022;14(1):e12332. doi:10.1002/DAD2.12332
Yuan A, Nixon RA. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front Neurosci. 2021;15:689938. doi:10.3389/FNINS.2021.689938
Abdelhak A, Foschi M, Abu‐Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158‐172. doi:10.1038/s41582‐021‐00616‐3
Czeiter E, Amrein K, Gravesteijn BY, et al. Blood biomarkers on admission in acute traumatic brain injury: relations to severity, CT findings and care path in the CENTER‐TBI study. EBioMedicine. 2020;56:102785. doi:10.1016/J.EBIOM.2020.102785
Zetterberg H, Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. 2016;12(10):563‐574. doi:10.1038/NRNEUROL.2016.127
Newcombe VFJ, Ashton NJ, Posti JP, et al. Post‐acute blood biomarkers and disease progression in traumatic brain injury. Brain. 2022;145(6):2064‐2076. doi:10.1093/BRAIN/AWAC126
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270. doi:10.1016/J.JALZ.2011.03.008
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263. doi:10.1016/J.JALZ.2011.03.005
Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord. 2007;21(3):249‐258. doi:10.1097/WAD.0B013E318142774E
Hughes TM, Lockhart SN, Suerken CK, et al. Hypertensive aspects of cardiometabolic disorders are associated with lower brain microstructure, perfusion, and cognition. J Alzheimers Dis. 2022;90(4):1589. doi:10.3233/JAD‐220646
Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR‐hyperintense white‐matter lesions in multiple Sclerosis. Neuroimage. 2012;59(4):3774‐3783. doi:10.1016/j.neuroimage.2011.11.032
Raz N, Yang Y, Dahle CL, Land S. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation‐related genetic variants. Biochim. Biophys. Acta, Mol. Basis Dis. 2012;1822(3):361‐369. doi:10.1016/J.BBADIS.2011.08.007
Oishi K, Faria A, Jiang H, et al. Atlas‐based whole brain white matter analysis using large deformation diffeomorphic metric mapping: application to normal elderly and Alzheimer's disease participants. Neuroimage. 2009;46(2):486. doi:10.1016/J.NEUROIMAGE.2009.01.002
Lockhart SN, Schaich CL, Craft S, et al. Associations among vascular risk factors, neuroimaging biomarkers, and cognition: preliminary analyses from the Multi‐Ethnic Study of Atherosclerosis (MESA). Alzheimers Dement. 2022;18(4):551‐560. doi:10.1002/ALZ.12429
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B. Ann Neurol. 2004;55(3):306‐319. doi:10.1002/ANA.20009
Mormino EC, Brandel MG, Madison CM, et al. Not quite PIB‐positive, not quite PIB‐negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59(2):1152. doi:10.1016/J.NEUROIMAGE.2011.07.098
Villeneuve S, Rabinovici GD, Cohn‐Sheehy BI, et al. Existing Pittsburgh Compound‐B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(7):2020. doi:10.1093/BRAIN/AWV112
Pérez‐Grijalba V, Romero J, Pesini P, et al. Plasma Aβ42/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J Prev Alzheimers Dis. 2019;6(1):34‐41. doi:10.14283/JPAD.2018.41
Fandos N, Pérez‐Grijalba V, Pesini P, et al. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement. 2017;8:179. doi:10.1016/J.DADM.2017.07.004
Schindler SE, Bateman RJ. Combining blood‐based biomarkers to predict risk for Alzheimer's disease dementia. Nature Aging. 2021;1(1):26‐28. doi:10.1038/s43587‐020‐00008‐0
Kassambra A. Pipe‐Friendly Framework for Basic Statistical Tests [R package rstatix version 0.6.0]. 2020. https://api.semanticscholar.org/CorpusID:230685253
Benjamini Y, Hochberg Y, Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser C. 1995;57(1):289‐300. doi:10.2307/2346101
Delanaye P, Mariat C. The applicability of eGFR equations to different populations. Nat Rev Nephrol. 2013;9(9):513‐522. doi:10.1038/NRNEPH.2013.143
Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009;20(11):2305‐2313. doi:10.1681/ASN.2009020171
Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022;18(12):2669‐2686. doi:10.1002/alz.12756
Yakoub Y, Ashton NJ, Strikwerda‐Brown C, et al. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease. Alzheimers Dement. 2023;19(12):5620‐5631. doi:10.1002/ALZ.13318. Published online 2023.
Gu Y, Honig LS, Kang MS, et al. Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multiethnic washington heights, inwood Columbia aging project cohort. medRxiv. 2023. Published online August 16, 2023. doi:10.1101/2023.08.11.23293967
Swaminathan S, Risacher SL, Yoder KK, et al. Association of plasma and cortical amyloid beta is modulated by APOE ε4 status. Alzheimers Dement. 2014;10(1):e9‐e18. doi:10.1016/J.JALZ.2013.01.007
Tang R, Panizzon MS, Elman JA, et al. Association of neurofilament light chain with renal function: mechanisms and clinical implications. Alzheimers Res Ther. 2022;14(1):189. doi:10.1186/s13195‐022‐01134‐0
Craft S, Claxton A, Baker LD, et al. Effects of regular and long‐acting insulin on cognition and Alzheimer's disease biomarkers: a pilot clinical trial. J. Alzheimer's Dis. 2017;57(4):1325‐1334. doi:10.3233/JAD‐161256
Benedict C, Grillo CA. Insulin resistance as a therapeutic target in the treatment of Alzheimer's disease: a state‐of‐the‐art review. Front Neurosci. 2018;12:215. doi:10.3389/FNINS.2018.00215
Bharadwaj P, Wijesekara N, Liyanapathirana M, et al. The link between type 2 diabetes and neurodegeneration: roles for Amyloid‐β, Amylin, and tau Proteins. J. Alzheimer's Dis. 2017;59(2):421‐432. doi:10.3233/JAD‐161192
Gonçalves RA, Wijesekara N, Fraser PE, De Felice FG. The link between tau and insulin signaling implications for Alzheimer's disease and other tauopathies. Front Cell Neurosci. 2019;13:17. doi:10.3389/FNCEL.2019.00017
Hall JR, Petersen M, Johnson L, O'Bryant SE. Characterizing plasma biomarkers of Alzheimer's in a diverse community‐based cohort: a cross‐sectional study of the HAB‐HD cohort. Front Neurol. 2022;13:1003. doi:10.3389/fneur.2022.871947
Schindler SE, Karikari TK, Ashton NJ, et al. Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light. Neurology. 2022;99(3):E245‐E257. doi:10.1212/WNL.0000000000200358
Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1‐15.e1‐4. doi:10.1016/J.JALZ.2014.07.003
Barnes LL, Bennett DA. Alzheimer's disease in African Americans: risk factors and challenges for the future. Health Aff. 2014;33(4):580‐586. doi:10.1377/hlthaff.2013.1353
Deniz K, Ho CCG, Malphrus KG, et al. Plasma biomarkers of Alzheimer's disease in African Americans. J. Alzheimer's Dis. 2021;79(1):323‐334. doi:10.3233/JAD‐200828
Benedet AL, Leuzy A, Pascoal TA, et al. Stage‐specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Brain. 2020;143(12):3793. doi:10.1093/BRAIN/AWAA342
Gauthreaux K, Kukull WA, Nelson KB, et al. Different cohort, disparate results: selection bias is a key factor in autopsy cohorts. Alzheimers Dement. 2024;20(1):266‐277. doi:10.1002/ALZ.13422
Jack CR, Wiste HJ, Algeciras‐Schimnich A, et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain. 2023;146(5):2029‐2044. doi:10.1093/BRAIN/AWAD042. Published online February 15, 2023.
Toledo JB, Vanderstichele H, Figurski M, et al. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011;122(4):401. doi:10.1007/S00401‐011‐0861‐8
Cipollini V, Troili F, Giubilei F. Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application. Int J Mol Sci. 2019;20(11):2812. doi:10.3390/IJMS20112812
Erhardt EB, Adair JC, Knoefel JE, et al. Inflammatory biomarkers aid in diagnosis of dementia. Front Aging Neurosci. 2021;13:717344. doi:10.3389/FNAGI.2021.717344/FULL
Quillen D, Hughes TM, Craft S, et al. Levels of Soluble interleukin 6 receptor and Asp358Ala are associated with cognitive performance and Alzheimer disease biomarkers. Neurol Neuroimmunol Neuroinflamm. 2023;10(3):e200095. doi:10.1212/NXI.0000000000200095
Hinman JD, Elahi F, Chong D, et al. Placental growth factor as a sensitive biomarker for vascular cognitive impairment. Alzheimers Dement. 2023;19(8):3519‐3527. doi:10.1002/ALZ.12974. Published online 2023.